( 您好!臺灣時間:2021/04/10 22:10
字體大小: 字級放大   字級縮小   預設字形  


研究生(外文):Shu-wei Lin
論文名稱(外文):Studies on 26S Proteasome Effected by Polyphenols
指導教授(外文):Tsui-ling Chang
外文關鍵詞:Poly ADP ribose polymeraseMethyl gallateGallic acidEllagic acidPro-caspase-3
  • 被引用被引用:1
  • 點閱點閱:646
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:11
  • 收藏至我的研究室書目清單書目收藏:0
根據行政院衛生署對國人所做的十大死亡原因報告中,近幾年惡性腫瘤一直是國人死因的第一名。蛋白質降解體在真核生物的細胞質中普遍存在,是真核生物中對於蛋白質降解作用的主要方法之一。1980年有學者發現在惡性腫瘤病患中都有蛋白質降解體活性異常增高現象;近年來有眾多學者以抑制蛋白質降解體活性為主要目的,提供作為癌症以及其他疾病的一種潛在性治療方式,以及癌症發生的預防。多酚類的化合物具有抗發炎以及預防細胞癌化作用;本研究目的為運用多酚類化合物來對蛋白質降解體進行活性抑制,首先選用了methyl gallate、gallic acid、ellagic acid、tannic acid等四種多酚類化合物及將前三項混合在一起的複方M+G+E,探討對於不同種類的癌症細胞內之蛋白質降解體的活性影響;運用對蛋白質降解活性分析、細胞存活、西方墨點法以及細胞週期,來觀察四種多酚類化合物對於肺癌細胞Hep-2和A549以及肝癌細胞HepG-2和Huh7癌細胞的影響。從目前的研究中顯示:(1)在四種的癌細胞中,這些多酚類化合物都有效的抑制蛋白質降解體的活性。(2)對於這四種癌細胞,各類的多酚類化合不僅有效的抑制蛋白質降解體並且進一步的促進細胞凋亡。(3)多酚類化合物在肺癌細胞A549中對於S5a和20S core具有調控作用,以及造成凋亡蛋白pro- caspase-3和Poly ADP ribose polymerase表現量的減少。(4)Tannic acid和M+G+E可以促進細胞週期走向細胞凋亡。綜合以上研究,多酚類化合物對於肝癌和肺癌細胞有效的抑制26S proteasome活性;複方M+G+E的效果也比單一methyl gallate、gallic acid、ellagic acid好。
According to the top ten causes of death report of the Department of Health, malignant tumors have been the first cause of death in recent year. 26S proteasome, which is widespread in the cytoplasm of eukaryotes, is one of the roles of protein degradation in eukaryotes. In 1980, researchers have found extraordinarily high activity of 26S proteasome in patients with cancer. In recent years, inhibiting the activity of 26S proteasome can provide potential treatments for cancer and other diseases, even for the cancer prevention. The compounds of polyphenols, have anti-inflammatory effects and can prevent cancer. At the first part of the study, four kinds of polyphenols are chosen: methyl gallate, gallic acid, ellagic acid, tannic acid and combinations M+G+E. The purpose of this study is to inhibit the activity of 26S proteasome by using polyphenol. These compounds are used to test the effect on 26S proteasome activity in different cancer cells. Hep-2 and A549 cells from lung cancer cell, HepG-2 and Huh7 cells from liver cancer cell are chosen 26S proteasome activity, cell viability, Western blotting and cell cycle are used to observe the effect of the four polyphenols on in cancer cells. In conclusions, the present study showed: (1) Among these four cancer cell lines, polyphenols inhibit the activity of 26S proteasome. (2) Polyphenols not only effectively inhibit the activity of 26S proteasome but also promote cell apoptosis. (3) The levels of S5a and 20S core were regulated by polyphenols in A549 cells. Reduced pro-caspase-3 and Poly ADP ribose polymerase were shown in this study. (4) Tannic acid and M+E+G promoter cell cycle toward apoptosis. In our study, we find polyphenols can inhibit the 26S proteasome activity in lung cancer and liver cancer. The effect of combinations M+G+E is better than that of methyl gallte, gallic acid, or ellagic acid.
中文摘要 i
Abstract ii
誌謝 iv
目錄 v
圖目錄 vii
表目錄 viii
縮寫對照表 1
第一章 緒論 2
1-1 研究背景 2
1-2 蛋白質降解體與癌症的關係 3
1-3 蛋白質降解體抑制劑 4
1-4 蛋白質降解 8
1-5 蛋白質降解體 9
1-6 泛素 11
1-7 細胞凋亡 13
1-8 多酚類化合物 14
1-9 細胞株簡介 16
1-10 研究目的 18
1-11 研究架構 19
第二章 材料與方法 20
2-1 材料 20
2-1-1 化學藥品及試劑 20
2-1-2 儀器與設備 21
2-1-3 多酚類化合物 22
2-1-4 細胞株 23
2-2 實驗方法 24
2-2-1 細胞培養 24
2-2-2 繼代細胞培養 24
2-2-3 細胞冷凍保存 24
2-2-4 細胞計數 25
2-2-5 多酚類化合物對細胞存活測試 26
2-2-6 多酚類化合物對26S proteasome的活性分析 26
2-2-7 蛋白質含量測定 27
2-2-8 蛋白質電泳 (SDS-PAGE) 27
2-2-9 西方墨點法 (Western Blotting) 28
2-2-10 細胞週期分析 (Cell cycle analysis) 29
第三章 結果 30
3-1 多酚類化合物對癌症細胞內26S proteasome 之活性分析 30
3-2 多酚類化合物對癌症細胞存活性測試 31
3-3 細胞凋亡特定蛋白表現現象在A549肺癌細胞中 32
3-4 多酚類化合物對於細胞週期影響現象在A549肺癌細胞中 34
第四章 討論 36
第五章 參考資料 50
Adams, J. (2004). "The development of proteasome inhibitors as anticancer drugs." Cancer Cell 5(5): 417-421.
Adams, J. and M. Kauffman (2004). "Development of the proteasome inhibitor Velcade (Bortezomib)." Cancer Invest 22(2): 304-311.
Agarwal, C., A. Tyagi, et al. (2006). "Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells." Mol Cancer Ther 5(12): 3294-3302.
Alsina, M., S. Trudel, et al. (2012). "A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma." Clin Cancer Res.
Amenta, J. S. and S. C. Brocher (1980). "Role of lysosomes in protein turnover: catch-up proteolysis after release from NH4Cl inhibition." J Cell Physiol 102(2): 259-266.
Bell, C. and S. Hawthorne (2008). "Ellagic acid, pomegranate and prostate cancer -- a mini review." J Pharm Pharmacol 60(2): 139-144.
Bennett, R. G. and R. S. Vetter (2004). "An approach to spider bites. Erroneous attribution of dermonecrotic lesions to brown recluse or hobo spider bites in Canada." Can Fam Physician 50: 1098-1101.
Bhat, T. K., B. Singh, et al. (1998). "Microbial degradation of tannins--a current perspective." Biodegradation 9(5): 343-357.
Boulares, A. H., A. G. Yakovlev, et al. (1999). "Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells." J Biol Chem 274(33): 22932-22940.
Chauhan, D., A. V. Singh, et al. (2010). "A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma." Blood 116(23): 4906-4915.
Clague, M. J., J. M. Coulson, et al. (2012). "Cellular functions of the DUBs." J Cell Sci 125(Pt 2): 277-286.
Escobar M, V. M., Belalcazar A, Santos ES, Raez LE. (2011). "The role of proteasome inhibition in nonsmall cell lung cancer." J Biomed Biotechnol.
Faried, A., D. Kurnia, et al. (2007). "Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines." Int J Oncol 30(3): 605-613.
Gallastegui, N. and M. Groll (2010). "The 26S proteasome: assembly and function of a destructive machine." Trends Biochem Sci 35(11): 634-642.
Groll, M., Y. Koguchi, et al. (2001). "Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor." J Mol Biol 311(3): 543-548.
Haince, J. F., G. G. Poirier, et al. (2004). "Nonisotopic methods for determination of poly(ADP-ribose) levels and detection of poly(ADP-ribose) polymerase." Curr Protoc Cell Biol Chapter 18: Unit18 17.
Han, Y. H., H. J. Moon, et al. (2009). "The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH." Oncol Rep 22(1): 215-221.
Hempel D, W. M., Kozłowski L, Romatowski J, Ostrowska H. (2011). "Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors." Tumor Biol.
Henry, L., T. Lavabre-Bertrand, et al. (2009). "Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis." Gut 58(6): 833-838.
Hochstrasser, M. (1995). "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation." Curr Opin Cell Biol 7(2): 215-223.
Hurchla, M. A., A. Garcia-Gomez, et al. (2012). "The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects." Leukemia.
Igney, F. H. and P. H. Krammer (2002). "Death and anti-death: tumour resistance to apoptosis." Nat Rev Cancer 2(4): 277-288.
Inoue, M., N. Sakaguchi, et al. (2000). "Role of reactive oxygen species in gallic acid-induced apoptosis." Biol Pharm Bull 23(10): 1153-1157.
Jakubowiak, A. J., D. Dytfeld, et al. (2012). "A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma." Blood.
Kawada, M., Y. Ohno, et al. (2001). "Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice." Anticancer Drugs 12(10): 847-852.
Kisselev, A. F. and A. L. Goldberg (2001). "Proteasome inhibitors: from research tools to drug candidates." Chem Biol 8(8): 739-758.
Kramer, H. B., B. Nicholson, et al. (2012). "Detection of ubiquitin-proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development." Biochim Biophys Acta.
Kumatori, A., K. Tanaka, et al. (1990). "Abnormally high expression of proteasomes in human leukemic cells." Proc Natl Acad Sci U S A 87(18): 7071-7075.
Lam, Y. A., T. G. Lawson, et al. (2002). "A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal." Nature 416(6882): 763-767.
Lee, H., Y. Kwon, et al. (2010). "Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells." J Immunol 185(11): 6698-6705.
Mandal, S. and G. D. Stoner (1990). "Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid." Carcinogenesis 11(1): 55-61.
Manosroi, J., K. Boonpisuttinant, et al. (2012). "Anti-proliferative activities on HeLa cancer cell line of Thai medicinal plant recipes selected from MANOSROI II database." J Ethnopharmacol 142(2): 422-431.
Manosroi, J., P. Dhumtanom, et al. (2006). "Anti-proliferative activity of essential oil extracted from Thai medicinal plants on KB and P388 cell lines." Cancer Lett 235(1): 114-120.
Moongkarndi, P., N. Kosem, et al. (2004). "Antiproliferation, antioxidation and induction of apoptosis by Garcinia mangostana (mangosteen) on SKBR3 human breast cancer cell line." J Ethnopharmacol 90(1): 161-166.
Moreau, P., P. G. Richardson, et al. (2012). "Proteasome inhibitors in multiple myeloma: 10 years later." Blood 120(5): 947-959.
Mujtaba, T. and Q. P. Dou (2012). "Black tea polyphenols inhibit tumor proteasome activity." In Vivo 26(2): 197-202.
Mullen, P. (2004). "PARP cleavage as a means of assessing apoptosis." Methods Mol Med 88: 171-181.
Nabhan, C., D. Villines, et al. (2012). "Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma." Clin Lymphoma Myeloma Leuk 12(1): 26-31.
Nam, S., D. M. Smith, et al. (2001). "Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis." Cancer Epidemiol Biomarkers Prev 10(10): 1083-1088.
Narayanan, B. A., O. Geoffroy, et al. (1999). "p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells." Cancer Lett 136(2): 215-221.
Parsons, J. L., Dianova, II, et al. (2011). "USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase beta." Mol Cell 41(5): 609-615.
Pettinari, A., M. Amici, et al. (2006). "Effect of polyphenolic compounds on the proteolytic activities of constitutive and immuno-proteasomes." Antioxid Redox Signal 8(1-2): 121-129.
Porter, A. G. and R. U. Janicke (1999). "Emerging roles of caspase-3 in apoptosis." Cell Death Differ 6(2): 99-104.
Ruiz, S., Y. Krupnik, et al. (2006). "The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia." Mol Cancer Ther 5(7): 1836-1843.
Seeram, N. P., L. S. Adams, et al. (2005). "In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice." J Nutr Biochem 16(6): 360-367.
Sullivan, J. A., K. Shirasu, et al. (2003). "The diverse roles of ubiquitin and the 26S proteasome in the life of plants." Nat Rev Genet 4(12): 948-958.
Thakur, V. S., K. Gupta, et al. (2012). "Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases." Carcinogenesis 33(2): 377-384.
Walters, K. J., A. M. Goh, et al. (2004). "Ubiquitin family proteins and their relationship to the proteasome: a structural perspective." Biochim Biophys Acta 1695(1-3): 73-87.
Whitley, A. C., G. D. Stoner, et al. (2003). "Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid--extensive binding to protein and DNA." Biochem Pharmacol 66(6): 907-915.
Yang, J., Z. Wang, et al. (2011). "Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats." Drug Metab Dispos 39(10): 1873-1882.
You, B. R. and W. H. Park (2010). "Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase." Toxicol In Vitro 24(5): 1356-1362.
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔